Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01265563 · ClinicalTrials.gov registry record · Phase 2
N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy
A Phase 2 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 108
- Enrollment target
NCT01265563: Completed Phase 2 study, sponsored by VA Office of Research and Development.
NCT01265563 is a Phase 2 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 108 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01265563, a Phase 2 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 108 participants
- Enrollment target
Study Summary
The study is done to find out whether the combined use of the nutritional supplements N-acetylcysteine and Siliphos (milk thistle extract) corrects the shedding of urine protein and oxidative damage (damage to cells and organs often compared to fast aging) in patients with Type 2 Diabetes Mellitus (T2DM) and diabetic kidney disease.
Interventions
- DRUG N-acetylcysteine placebo and silibin placebo
- DRUG N-acetylcysteine active and silibin placebo
- DRUG N-acetylcysteine placebo and silibin active
- DRUG N-acetylcysteine active and silibin active
- DRUG N-acetylcysteine active + high-dose silibin active
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2011-01 |
| Est. Completion | 2016-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01265563
The ClinicalTrials.gov registry entry for NCT01265563 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which N-acetylcysteine placebo and silibin placebo is the first listed.
NCT01265563 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01265563 about?
NCT01265563 is a clinical study titled "N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy". The study is done to find out whether the combined use of the nutritional supplements N-acetylcysteine and Siliphos (milk thistle extract) corrects the shedding of urine protein and oxidative damage (damage to cells and organs often compared to fast aging) in patients with Type 2 Diabetes Mellitus (...
What is the current status of trial NCT01265563?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 108 participants. The study started on 2011-01. Estimated completion is 2016-12.
What interventions are being tested in trial NCT01265563?
The interventions under investigation include: N-acetylcysteine placebo and silibin placebo (DRUG), N-acetylcysteine active and silibin placebo (DRUG), N-acetylcysteine placebo and silibin active (DRUG), N-acetylcysteine active and silibin active (DRUG), N-acetylcysteine active + high-dose silibin active (DRUG).
Who is sponsoring clinical trial NCT01265563?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.